Solstein Capital, LLC Regeneron Pharmaceuticals, Inc. Transaction History

Solstein Capital, LLC

$196 Million
Q3 2024

A detailed history of Solstein Capital, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Solstein Capital, LLC holds 299 shares of REGN stock, worth $226,286. This represents 0.16% of its overall portfolio holdings.

Number of Shares

299

Previous 299 -0.0%

Holding current value

$226,286

Previous $314,000 -0.0%

% of portfolio

0.16%

Previous 0.2%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 26, 2024	SELL	$883.2 - $1071.19 $63,590 - $77,125	-72 Reduced 19.41%	299 $314,000
Q3 2023 Oct 25, 2023	SELL	$692.45 - $844.37 $8,309 - $10,132	-12 Reduced 3.13%	371 $305,000
Q2 2023 Jul 27, 2023	BUY	$700.03 - $830.35 $21,000 - $24,910	30 Added 8.5%	383 $275,000
Q1 2023 Apr 19, 2023	BUY	$680.49 - $826.97 $60,563 - $73,600	89 Added 33.71%	353 $290,000
Q4 2022 Feb 02, 2023	SELL	$705.89 - $766.39 $11,294 - $12,262	-16 Reduced 5.71%	264 $190,000
Q3 2022 Nov 01, 2022	BUY	$573.97 - $724.32 $2,869 - $3,621	5 Added 1.82%	280 $193,000
Q2 2022 Aug 09, 2022	SELL	$548.35 - $738.84 $2,741 - $3,694	-5 Reduced 1.79%	275 $163,000
Q1 2022 May 05, 2022	SELL	$595.12 - $698.43 $439,198 - $515,441	-738 Reduced 72.5%	280 $196,000
Q4 2021 Jan 27, 2022	BUY	$543.48 - $670.97 $526,632 - $650,169	969 Added 1977.55%	1,018 $643,000
Q2 2021 Aug 12, 2021	BUY	$472.8 - $558.54 $945 - $1,117	2 Added 4.26%	49 $27,000
Q1 2021 May 13, 2021	BUY	$446.73 - $548.2 $20,996 - $25,765	47 New	47 $22,000
Q4 2020 Feb 11, 2021	SELL	$478.3 - $607.98 $22,480 - $28,575	-47 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$274.13 - $376.51 $12,884 - $17,695	47 New	47 $18,000

Others Institutions Holding REGN

# of Institutions

1,529

Shares Held

84.1M

Call Options Held

1.22M

Put Options Held

1.51M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $81.1B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Solstein Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Solstein Capital, LLC with notifications on news.

Account

Solstein Capital, LLC Regeneron Pharmaceuticals, Inc. Transaction History